PURPOSE: Molecules which are exclusively or preferentially expressed by malignant cells are potential targets for immunotherapeutic approaches to the treatment of cancer. METHODS: We therefore tested serum samples of 95 patients with aggressive B-cell lymphomas for antibodies against lymphoma-associated molecules using SEREX for antibodies against BCL-2, BCL-XL, MCL-1, survivin, BCL-6, CD20, LM02, PDE4B, cyclin-D2, actinin-alpha1, SCYA3, PKCbeta2, E2IG3, and HGAL. RESULTS: One patient had low-titered (1:100) antibodies against PKCbeta2. Antibodies against BCL-2 were detected in the sera of five patients (5.3%), with responses found more frequently in follicular lymphoma grade 3 (3/26 or 11.5%) than in diffuse large B-cell lymphomas (2/67 or 3%). Anti-BCL-2 antibodies were of the IgG class and titers ranged from 1:1,000 to 1:100,000 with highest titers before treatment and decreasing slowly during remission. CONCLUSION: The spontaneous immunogenicity of BCL-2 makes this molecule a prime candidate for vaccine approaches in BCL-2 positive B-cell lymphomas.
PURPOSE: Molecules which are exclusively or preferentially expressed by malignant cells are potential targets for immunotherapeutic approaches to the treatment of cancer. METHODS: We therefore tested serum samples of 95 patients with aggressive B-cell lymphomas for antibodies against lymphoma-associated molecules using SEREX for antibodies against BCL-2, BCL-XL, MCL-1, survivin, BCL-6, CD20, LM02, PDE4B, cyclin-D2, actinin-alpha1, SCYA3, PKCbeta2, E2IG3, and HGAL. RESULTS: One patient had low-titered (1:100) antibodies against PKCbeta2. Antibodies against BCL-2 were detected in the sera of five patients (5.3%), with responses found more frequently in follicular lymphoma grade 3 (3/26 or 11.5%) than in diffuse large B-cell lymphomas (2/67 or 3%). Anti-BCL-2 antibodies were of the IgG class and titers ranged from 1:1,000 to 1:100,000 with highest titers before treatment and decreasing slowly during remission. CONCLUSION: The spontaneous immunogenicity of BCL-2 makes this molecule a prime candidate for vaccine approaches in BCL-2 positive B-cell lymphomas.
Authors: Margaret A Shipp; Ken N Ross; Pablo Tamayo; Andrew P Weng; Jeffery L Kutok; Ricardo C T Aguiar; Michelle Gaasenbeek; Michael Angelo; Michael Reich; Geraldine S Pinkus; Tane S Ray; Margaret A Koval; Kim W Last; Andrew Norton; T Andrew Lister; Jill Mesirov; Donna S Neuberg; Eric S Lander; Jon C Aster; Todd R Golub Journal: Nat Med Date: 2002-01 Impact factor: 53.440
Authors: Izidore S Lossos; Debra K Czerwinski; Ash A Alizadeh; Mark A Wechser; Rob Tibshirani; David Botstein; Ronald Levy Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Susan O'Brien; Joseph O Moore; Thomas E Boyd; Loree M Larratt; Aleksander Skotnicki; Benjamin Koziner; Asher A Chanan-Khan; John F Seymour; R Gregory Bociek; Steve Pavletic; Kanti R Rai Journal: J Clin Oncol Date: 2007-02-12 Impact factor: 44.544
Authors: Stefano Monti; Kerry J Savage; Jeffery L Kutok; Friedrich Feuerhake; Paul Kurtin; Martin Mihm; Bingyan Wu; Laura Pasqualucci; Donna Neuberg; Ricardo C T Aguiar; Paola Dal Cin; Christine Ladd; Geraldine S Pinkus; Gilles Salles; Nancy Lee Harris; Riccardo Dalla-Favera; Thomas M Habermann; Jon C Aster; Todd R Golub; Margaret A Shipp Journal: Blood Date: 2004-11-18 Impact factor: 22.113
Authors: Thomas A Buchholz; Darren W Davis; David J McConkey; W Fraser Symmans; Vicente Valero; Anuja Jhingran; Susan L Tucker; Lajos Pusztai; Massimo Cristofanilli; Francisco J Esteva; Gabriel N Hortobagyi; Aysegul A Sahin Journal: Cancer J Date: 2003 Jan-Feb Impact factor: 3.360
Authors: J C Reed; T Miyashita; S Takayama; H G Wang; T Sato; S Krajewski; C Aimé-Sempé; S Bodrug; S Kitada; M Hanada Journal: J Cell Biochem Date: 1996-01 Impact factor: 4.429
Authors: O Türeci; Y T Chen; U Sahin; A O Güre; C Zwick; C Villena; S Tsang; G Seitz; L J Old; M Pfreundschuh Journal: Int J Cancer Date: 1998-07-03 Impact factor: 7.396